Femoropopliteal dissection repair using the **Tack Endovascular System** following plain balloon angioplasty (POBA)

- 138 subjects at 13 European sites
- 100% freedom from MAE at 30 days
- 98.5% dissection resolution
- 76.4% K-M Patency at 12 months
- 89.5% K-M Freedom from CD-TLR at 12 months
Infrapopliteal dissection repair using the Tack Endovascular System following plain balloon angioplasty (POBA)

- 35 subjects at 6 Europe/New Zealand sites
- 97.1% freedom from MALE + POD at 30 days
- 78.4% K-M Patency at 12 months
- 93.5% K-M Freedom from CD-TLR at 12 months
Femoropopliteal dissection repair using the **Tack Endovascular System** following plain balloon angioplasty (POBA) or Lutonix® drug-coated balloon angioplasty.

- 213 subjects at 33 US/Europe sites
- 100% freedom from MAE at 30 days
- 92.1% Dissection Resolution
- 79.3% K-M Patency at 12 months
- 86.5% K-M Freedom from CD-TLR at 12 months
- 0.5% Bail out stent rate

Lutonix® is a registered trademark of BD Interventional.
Femoropopliteal dissection repair using the **Tack Endovascular System** following **IN.PACT® Admiral®** drug-coated balloon angioplasty

- 201 subjects at 14 European sites
- 169 subjects with lesions $\geq 20$ and $\leq 150$ mm
- 32 subjects with lesions $>150$ and $\leq 250$ mm

| Endpoints   | Safety: 30-Day freedom from MAE | Efficacy: Freedom from CD-TLR and DUS-derived binary restenosis |

IN.PACT® Admiral® are registered trademarks of Medtronic, Inc.
Infrapopliteal dissection repair using the Tack Endovascular System following plain balloon angioplasty (POBA)

- 233 subjects enrolled at 41 US, European and New Zealand sites

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Safety: MALE + POD at 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Efficacy: 6-Month MALE + POD at 30 days</td>
</tr>
</tbody>
</table>
REFERENCES

INTENDED USE: The Tack Endovascular System (6F) is intended for use in the superficial femoral and proximal popliteal arteries ranging in diameter from 3.5mm to 6.0mm for the repair of post percutaneous transluminal balloon angioplasty (PTA) dissection(s).

CONTRAINDICATIONS FOR USE: The Tack Endovascular System is contraindicated for the following: 1. Patients with residual stenosis in the treated segment equal to or greater than 30% after PTA. 2. Tortuous vascular anatomy significant enough to prevent safe introduction and passage of the device. 3. Patients with a known hypersensitivity to nickel-titanium alloy (Nitinol). 4. Patients unable to receive standard medication used for interventional procedures such as anticoagulants, contrast agents and antiplatelet therapy.

Prior to using the Tack Endovascular System, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

The Tack Endovascular System is CE Mark authorized under EC Directive 93/42/EEC. Adaptive Sizing™ is a trademark of Intact Vascular, Inc. Tack Endovascular System® and Tack® are registered trademarks of Intact Vascular, Inc.
Copyright © 2019. All rights reserved.

MKT-0135 Rev 01 GLOBAL 042019

www.intactvascular.com